engleski

Overall survival among patients diagnosed with B-chronic lymphocytic leukemia with 17p deletion status (del(17p))

Introduction: The B-chronic lymphocytic leukemia (B-CLL) is the prototype of B-cell chronic lymphatic malignancies and one of the most common leukemia in adults. So far, various prognostic markers of B-CLL have been validated and are routinely used in clinical practice. The aim of the study was to investigate the prognostic role of chromosome 17p deletion (del(17p)) among patients with B-CLL. Methods: The study enrolled 197 patiens (104 males, age 71± 11 years ; 93 feemales ; age 68±9 years) with B-CLL. The tumor lymphocytes samples were collected from peripheral blood. Tumor DNA was extracted using QIAamp Blood DNA and Oragene DNA kits respectively, according to the manufacturer´s directions. FISH cytogenetics were assessed by the official clinical cytogenetics laboratory. The cutoff for 17p deletion was 10% cells positive. Overall survival (OS) was estimated using the Kaplan- Meier method. Results: From total number of 197 subjects, 48 (24.36%) (31 male (64.58%) and 17 feemales (35.41%) had del(17p) and 149 (75.63%) subjects were without this mutation. The OS among subjects with del(17p) was 35 months versus 58 months in subjects without del(17p) (p< 0.001). Conclusions: Our study indicates that 17p deletion status is associated with shorter OS. These results have direct impact on clinical prognosis and outcome as well as for future therapy of B-CLL.

B-chronic lymphocytic leukemia, del(17p)

nije evidentirano